COMMUNIQUÉS West-GlobeNewswire

Jean Health Announces Expansion into Australia: Solving Urgent Rural Maternity Care Needs
18/10/2024
Jean Health has announced its expansion into Australia to address the urgent maternity care needs in rural areas. The company aims to improve maternal health outcomes through its AI-driven platform, create jobs, and [...]
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
18/10/2024
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the [...]
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
18/10/2024
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testing, and [...]
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis
18/10/2024
The pace of patient enrollment has significantly accelerated following a summertime slowdown DENVER, Oct. 18, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device [...]
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
18/10/2024
Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, NJ. [...]
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
18/10/2024
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades 1 Second approval of ZORYVE outside of the United States, expanding [...]
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
18/10/2024
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the [...]
Alignment Healthcare to Announce Third Quarter 2024 Financial Results and Host Conference Call Tuesday, Oct. 29, 2024
18/10/2024
ORANGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2024 financial results on Tuesday, Oct. 29, 2024, after market close. Following the release, [...]
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
18/10/2024
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
UPDATE -- Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health Acquisition
18/10/2024
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets, people, and families Combined 2025 revenue and EBITDA expected to be approximately +$270 [...]
Phase III trial results of novel triple combination pill for hypertension published in The Lancet
18/10/2024
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual therapy, with good [...]
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
18/10/2024
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK , 18 October 2024 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, [...]
KFSHRC Leads Healthcare Intelligence in Diagnostics and Patient Care
18/10/2024
RIYADH, Saudi Arabia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is contributing to global healthcare innovation, leveraging artificial intelligence (AI) and [...]
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
18/10/2024
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Oct. 18, [...]
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
18/10/2024
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ® ( [...]
Le KFSHRC présente ses dernières innovations et solutions de santé à l’occasion de la Global Health Exhibition 2024
18/10/2024
RIYAD, Arabie saoudite, 18 oct. 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) participera comme principal sponsor (Platine) à l’édition 2024 du Forum mondial de la santé ( [...]
Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health Acquisition
18/10/2024
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets, people, and families Combined 2025 revenue and EBITDA expected to be approximately +$270 [...]
Nxera Pharma to Host R&D Day 2024
18/10/2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date : Wednesday, 6 November 2024 [...]
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
18/10/2024
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of [...]

Pages